Moditen Depo (Fluphenazine Decanoate)

• Fluphenazine decanoate is a typical antipsychotic used in the management of dopamine‑mediated psychotic disorders.
• Schizophrenia: Reduces positive symptoms such as hallucinations and delusions, improving overall functioning.
• Acute psychotic episodes: Provides rapid symptom control when administered as a depot formulation.
• Maintenance therapy for chronic psychosis: Sustains therapeutic plasma levels over weeks, supporting adherence and relapse prevention.

• Fluphenazine decanoate exerts its antipsychotic effect primarily by antagonizing dopamine D2 receptors in the mesolimbic pathway, thereby decreasing dopaminergic neurotransmission. It also blocks other central receptors, including muscarinic, histamine H1, and alpha‑adrenergic sites, contributing to its broader pharmacologic profile and side‑effect spectrum.

Fluphenazine decanoate may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects

• Extrapyramidal symptoms: Tremor, rigidity, bradykinesia, or akathisia.
• Sedation: Drowsiness or reduced alertness.
• Anticholinergic effects: Dry mouth, constipation, blurred vision.
• Weight gain: Increased appetite leading to modest weight increase.

Serious or Rare Side Effects

• Neuroleptic malignant syndrome: Life‑threatening hyperthermia, severe muscle rigidity, autonomic instability.
• Tardive dyskinesia: Persistent involuntary movements that may be irreversible.
• Cardiovascular events: Orthostatic hypotension, arrhythmias, or QT‑interval prolongation.

• When prescribing fluphenazine decanoate, clinicians should observe several safety measures.
• Monitor for extrapyramidal symptoms: Assess motor function regularly.
• Screen for metabolic changes: Check weight, glucose, and lipid levels periodically.
• Assess cardiovascular status: Observe blood pressure and heart rate, especially after the first dose.
• Avoid use in patients with known hypersensitivity to phenothiazines: Discontinue if a reaction occurs.
• Pregnancy and lactation: Use only if benefits outweigh risks; data are limited.
• Store at ambient temperature: Keep below 25°C, protect from moisture and light, retain in original packaging.

Fluphenazine decanoate interacts with several drug classes that may alter its safety or efficacy.

Major Interactions (Avoid)

• CYP1A2 inhibitors (e.g., fluvoxamine): May increase fluphenazine levels, raising toxicity risk.
• Anticholinergic drugs (e.g., benztropine): May exacerbate anticholinergic side effects.
• QT‑prolonging agents (e.g., haloperidol): Combined use can increase risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely)

• CNS depressants (e.g., benzodiazepines, alcohol): Additive sedation; monitor level of consciousness.
• Dopamine agonists (e.g., levodopa): May reduce antipsychotic efficacy; adjust therapy as needed.
• Lithium: May increase risk of neuroleptic malignant syndrome; monitor closely.